LBMON176 Management, Safety, And Efficacy Of Osilodrostat Treatment In US Patients With Non-pituitary Cushing's Syndrome: Results From The ILLUSTRATE Study

BACKGROUND: Osilodrostat, a potent cortisol synthesis inhibitor, demonstrated safety and efficacy in the treatment of Cushing's disease (CD). No information is available describing use of osilodrostat in non-pituitary Cushing's syndrome (CS) in US patients. Data from a real-world study in...

Descripción completa

Detalles Bibliográficos
Autores principales: Auchus, Richard Joseph, Fleseriu, Maria, Huang, Wenyu, Spencer-Segal, Joanna L, Yuen, Kevin Choong Ji, Dacus, Kelley C, Ludlam, William Henry, Babler, Elizabeth Kay, Das, Ashis K, Campos, Cynthia, Broder, Michael S, Ioachimescu, Adriana Gabriela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627142/
http://dx.doi.org/10.1210/jendso/bvac150.982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627142/
http://dx.doi.org/10.1210/jendso/bvac150.982

Ejemplares similares